Approved comparison material connected to this topic.
19 total recordsSource comparisons are presented without a generated winner.
10mg 1mL 10mg/mL 0.025mL / 2.5 units 0.05mL / 5 units 0.1mL / 10 units High concentration. Smallest volumes, hardest to measure accurately below 5 units 2mL 5mg/mL 0.2mL / 20 units Optimal for most protocols. …
Different research goals require different dosing strategies. The table below compares three common Melanotan-2 protocols based on objective, dose range, frequency, and duration. Conservative Loading 0.25–0.5m…
Standard Protocol (2mL BAC water) 2.0mL 2.5mg/mL Low if air-injection avoided 30 days at 2–8°C Optimal balance of concentration, stability, and ease of dosing. Industry standard for multi-dose research vials H…
The table below compares three MT2 dosing strategies: conservative (minimal side effects, slower pigmentation), standard (balanced), and aggressive (faster pigmentation, higher side effect frequency during loa…
Both compounds stimulate melanin production, but their pharmacological profiles differ significantly. Receptor selectivity MC1R selective MC1R, MC3R, MC4R, MC5R (non-selective) Tanning effect Slower, more grad…
Type I-II (Very Fair) 0.25mg daily, increase to 0.5mg after week 1 4–6 weeks 0.5mg twice weekly 3–4 weeks with minimal UV exposure Slowest responders due to low melanocyte density. Patience and conservative UV…
0.1–0.2mg daily 20–40% 4–6 hours, inconsistent <5% Minimal to none Subtherapeutic for appetite. Insufficient receptor activation for reliable satiety signaling 0.25–0.5mg daily 60–85% 8–12 hours, consistent 10…
Loading Phase 0.25mg Daily for 5–7 days 2–4 hours post-injection MC1R priming, minimal pigmentation, reduced nausea risk Start here. Receptor saturation without off-target effects Escalation Phase 0.5–1.0mg Da…
Most published protocols differentiate between loading phases and maintenance dosing. A loading phase involves daily low-dose administration (0.25–0.5mg) for 3–7 days to gradually upregulate melanocortin recep…
0.25–0.5mg daily Mild increase in sexual desire; noticeable arousal threshold reduction after 3–5 days 3–4 hours / 6 hours Minimal. Mild flushing in 15–20% Lowest dose range tested in Phase II female arousal t…
| Protocol Type | Loading Dose | Duration | Maintenance Dose | UV Exposure Timing | Side Effect Profile | Professional Assessment ||—|—|—|—|—|—|| Conservative (Fitzpatrick I–II) | 0.25mg daily → 0.5mg daily | …
Loading Phase + Maintenance 0.25–0.5mg daily for 5–7 days, then 1–1.5mg as needed Daily loading, then 2–3×/week 15–25% during loading, <10% at maintenance 90–180 minutes post-injection Lowest side effect profi…
Acute administration. Single doses timed 45–120 minutes before desired sexual activity. Relies on plasma peak concentration aligning with the activity window. MT-2 administered subcutaneously reaches Cmax (max…
Conservative (evidence-based) 0.25mg daily × 5–7 days, then 0.5mg daily 10–14 days 15–20% 0.5mg 2×/week Prioritises tolerability; slower onset but higher compliance Moderate (hybrid) 0.5mg daily from day 1 7–1…
0.1–0.25mg daily Minimal appetite reduction; threshold MC4R activation Very low. No visible darkening in most users 20–30% during first week Initial sensitivity testing; pediatric research contexts Subtherapeu…
Loading (Type I–II) 0.25–0.5mg daily 10–14 days Visible tan by day 7–10; moderate depth by day 14 Nausea 15–25%, flushing 10–20%, minimal sexual sides at low dose Best for fair skin. Slow ramp minimises uneven…
| Protocol Type | Dose Range | Administration Timing | Onset Window | Duration of Effect | Receptor Mechanism | Side Effect Profile ||—|—|—|—|—|—|| Acute Single-Dose | 0.5–1mg | 60–90 min pre-activity | 45–120…
Type I (very fair, always burns) 0.25mg daily 14–21 days 0.25–0.5mg 2–3×/week 10 min/session, 2×/week Light tan (2–3 shades darker than baseline) Requires longest titration; MC1R density is lowest, so receptor…
The following table compares Melanotan-2 dosing tiers for erectile function against key efficacy and safety markers based on clinical observations and user-reported data from research contexts. 0.25mg subcutan…